Novartis Kymriah® CAR-T cell therapy OKd for follicular lymphoma

 

• 68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile¹
• Sustained clinical benefit from Kymriah treatment demonstrated – of patients who achieved a complete response, 85% were still in response at 12 months¹
• Kymriah can be administered in the outpatient setting, offering increased flexibility and potentially reducing the burden of therapy for patients and their care teams^1,2
• Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings¹

https://www.biospace.com/article/releases/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma/